Neurogen, Results of Multiple Ascending Dose Studies with Experimental Obesity Drug

Jan 07, 2008 - Neurogen Corporation (Nasdaq: NRGN) announced that it has completed the follow-up component of a Phase 1 multiple ascending dose (MAD) study with NGD-4715, an MCH-1 receptor antagonist being investigated for the treatment of obesity.The initial phase of the MAD study utilized three times per day dosing (tid) for 14 days in healthy obese subjects exposed to a high caloric diet. As previously reported, during this phase moderate induction of the liver enzyme CYP 3A4 occurred, increasing the probability of accelerating metabolism of other drugs administered concomitantly. In addition, during the initial phase of the MAD study, lipid lowering effects were observed... Neurogen's Press Release-